Omalizumab for the treatment of chronic spontaneous urticaria in clinical practice
Maria Rita Bongiorno(University of Palermo), Giuseppe Valenti(University of Palermo), Emilio Raia(Presidio Ospedaliero), Alberto Allotta(Azienda di Rilievo Nazionale ed Alta Specializzazione), Mirella Milioto(Azienda di Rilievo Nazionale ed Alta Specializzazione), Giuseppe Pistone(University of Palermo), Antonino Arena, Giovanna Malara(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Enrico Heffler(Humanitas University), Ignazio Brusca(Ospedale Buccheri la Ferla Fatebenefratelli), Nunzio Crimi(University of Catania), Morena Porto(University of Catania), Salvatore Corrao(Azienda di Rilievo Nazionale ed Alta Specializzazione)
Cited by 14
Related Papers
EUFOREA consensus on biologics for CRSwNP with or without asthma
|Allergy|2019|378
Eosinophilic and Noneosinophilic Asthma
|CHEST Journal|2021|262
Toward clinically applicable biomarkers for asthma: An <scp>EAACI</scp> position paper
|Allergy|2019|192
Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study*
|British Journal of Dermatology|2020|175
Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets
|Frontiers in Pharmacology|2022|157